Positron emission tomography of herpes simplex virus 1 oncolysis

Cancer Research

Volumn 67, Issue 7, 2007, Pages 3295-3300

  Kuruppu, Darshini ^a   Brownell, Anna Liisa ^a   Zhu, Aijun ^a   Yu, Meixiang ^a   Wang, Xukui ^a   Kulu, Yakup ^a   Fuchs, Bryan C ^a   Kawasaki, Hiroshi ^a   Tanabe, Kenneth K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 (4 FLUORO 3 [HYDROXYMETHYL]BUTYL)GUANINE F 18; FLUOROTHYMIDINE F 18; ONCOLYTIC HERPES SIMPLEX VIRUS 1; ONCOLYTIC HERPES VIRUS; THYMIDINE KINASE; TRACER; UNCLASSIFIED DRUG; 9 (4 ((18)F)FLUORO 3 HYDROXYMETHYLBUTYL)GUANINE; 9-(4-((18)F)FLUORO-3-HYDROXYMETHYLBUTYL)GUANINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; GUANINE; RADIOPHARMACEUTICAL AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; ENZYME SUBSTRATE; HERPES SIMPLEX VIRUS 1; IN VIVO STUDY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; VIRUS REPLICATION; ANIMAL; BIOSYNTHESIS; CELL GROWTH; CERCOPITHECUS; COLON TUMOR; GENETICS; METABOLISM; METHODOLOGY; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PHYSIOLOGY; SCINTISCANNING; VIROLOGY;

ANIMALS; CELL GROWTH PROCESSES; CERCOPITHECUS AETHIOPS; COLONIC NEOPLASMS; FLUORINE RADIOISOTOPES; GUANINE; HERPESVIRUS 1, HUMAN; MICE; ONCOLYTIC VIROTHERAPY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THYMIDINE KINASE; VIRUS REPLICATION;

EID: 34248136542     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4062     Document Type: Article

References (38)

1. Dranoff G. Cancer gene therapy: connecting basic research with clinical inquiry. J Clin Oncol 1998;16:2548-56.
2. Johnson PA, Miyanohara A, Levine F, Cahill T, Friedmann T. Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1. J Virol 1992:66:2952-65.
3. Roizman B, Sears AE. Herpes simplex viruses and their replication. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology. 3rd ed. Philadelphia: Lippincott-Raven; 1996. p. 2231-95.
4. Martuza RL. Conditionally replicating herpes vectors for cancer therapy. J Clin Invest 2000;105:841-6.
5. Stojdl DF, Lichty R, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000:6:821-5.
6. Wilcox ME, Yang W, Senger D, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 2001;93:903-12.
7. Kasuya H, Pawlik TM, Mullen JT, et al. Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res 2004;64:2561-7.
8. Yazaki T, Manz HJ, Rabkin SD, Martuza RL. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 1995;55:4752-6.
9. Sinkovics JG, Horvath JC. Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 2000;16:1-15.
10. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999;59:410-3.
11. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998;282:1332-4.
12. Mullen JT, Tanabe KK. Viral oncolysis. Oncologist 2002;7:106-19.
13. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002;2:938-50.
14. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1 infected cells can compensate for the loss of the large unit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 1988;166:41-51.
15. Mullen JT, Kasuya H, Yoon SS, et al. Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann Surg 2002;236:502-12; discussion 12-3.
16. Yoon SS, Nakamura H, Carroll NM, et al. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J 2000;14:301-11.
17. Kooby DA, Carew JF, Halterman MW, et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999;13:1325-34.
18. Chase M, Chung R, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol 1998;16:444-8.
19. Nakamura H, Mullen JT, Chandrasekhar S, et al. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 2001;61:5447-52.
20. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-74.
21. Fong Y, Kemeny N, Jarnagin W, et al. Phase I study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases [abstract]. Proc Am Soc Clin Oncol 2002;21:8.
22. MacKie RM, Stewart B, Brown SM. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001;357:525-6.
23. Tjuvajev JG, Doubrovin M, Akhurst T, et al. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med 2002;43:1072-83.
24. Kramm CM, Chase M, Herrlinger U, et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997;8:2057-68.
25. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002;2:683-93.
26. Blasberg R. PET imaging of gene expression. Eur J Cancer 2002;38:2137-46.
27. Nakamura H, Kasuya H, Mullen JT, et al. Regulation of Herpes simplex virus g134.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest 2002;109:871-82.
28. Rampling R, Cruickshank G, Papanastassiou V et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7:859-66.
29. Harrow S, Papanastassiou V, Harland J, et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 2004;11:1648-58.
30. Papanastassiou V, Rampling R, Fraser M, et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 2002;9:398-406.
31. Advani SJ, Sibley GS, Song PY, et al. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene Ther 1998;5:160-5.
32. Boviatsis EJ, Park JS, Sena-Esteves M, et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 1994;54:5745-51.
33. Kurihara T, Brough DE, Kovesdi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000;106:763-71.
34. Parikh NS, Currier MA, Mahller YY, et al. Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer 2005;44:469-78.
35. Shah K, Jacobs A, Breakefield XO, Weissleder R Molecular imaging of gene therapy for cancer. Gene Ther 2004;11:1175-87.
36. Schellingerhout D, Rainov NG, Breakefield XO, Weissleder R. Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Ther 2000;7:1648-55.
37. Bennett JJ, Tjuvajev J, Johnson P, et al. Positron emission tomography imaging for herpes virus infection: implications for oncolytic viral treatments of cancer. Nat Med 2001;7:859-63.
38. Jacobs A, Tjuvajev JG, Dubrovin M, et al. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res 2001;61:2983-95.